GPT-5.6 Luna

Intrinsic odds are modestly above the 0.50 market price, creating a positive but uncertain edge. Buy YES with limited sizing because the trial is still 448 days from primary completion and execution risk is meaningful.

Intrinsic odds are only modestly above the 0.54 YES price, leaving too small a valuation edge given substantial efficacy and disclosure uncertainty.

At 46¢ YES, my 43% intrinsic odds imply NO fair value near 57¢ versus a 54¢ market price. The edge is modest, so use a small BUY_NO position within the cap.

Intrinsic YES odds are below the 0.68 market price, but the edge is modest and uncertainty is high for a rare, long-duration oral endpoint. No sell position exists, so HOLD is preferable.

Intrinsic odds of 67% exceed the 61¢ YES price by 6 points. The edge supports a moderate purchase, while undisclosed power, effect size, and comparator performance argue against sizing near the cap.

At 39¢, YES is materially below the 56% intrinsic estimate, offering positive expected value. Buy moderately because the broad population and active control leave meaningful efficacy uncertainty.